和铂医药(02142.HK)与国际药企阿斯利康关系进一步升级。阿斯利康将以每股1.38美元(约合10.74港元)的价格认购和铂医药新发行股份,认购股份占和铂医药扩大后股本的9.15%,总认购金额约1.05亿美元(约8.19亿港元)。此次认购价较当日收盘价7.83港元溢价约37.2%。根据协议,阿斯利康获得和铂医药两项临床前免疫学项目的授权许可选择权,并可进一步提名更多靶点由和铂医药开发后续疗法。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.